| CAS: | 536697-79-7 | |
| 分子式: | C19H26O2 | |
| 分子量: | 286.4 | |
| 中文名称: |
| |
| 用途: | O-1918 is a cannabidiol analog which acts as a selective antagonist of abnormal cannabidiol at the non-CB1/CB2 endothelial receptor. |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||
| O912450 | MACKLIN | O-1918 | 98%, 10 mg/mL methyl acetate | 799元/1mg; 3800元/5mg; | 咨询 | ||
储存：-20°C，密闭，干燥 状态：液体 | |||||||
| HY-103335 | MCE | O1918,536697-79-7_MCE(MedChemExpress) | 1100元/1 mg (34.91 mM * 100 μL in Methyl acetate); 3800元/5 mg (34.91 mM * 500 μL in Methyl acetate); 6000元/10 mg (34.91 mM * 1 mL in Methyl acetate); | 咨询 | |||
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。 O1918MCE 国际站：O1918 品牌：MedChemExpress (MCE) 货号：HY-103335 CAS 号：536697-79-7 生物活性：O1918 是一种选择性非 CB1 受体和 GPR18 拮抗剂。 体内研究(In Vivo)：Decreases in HR, blood pressure, MBF and RBF by about 20 beats/min, 5-10 mmHg and 0.7 and 0.2 mL/min, respectively, are observed after injection of O1918 (3 μmol/kg). O1918 causes an inhibition of the anandamide-stimulated decreases in MBP, SBP and DBP by 55, 38 and 42% respectively. Similarly, this antagonist reduces the methanandamide-stimulated fall in SBP and DBP by 44 and 32%, respectively, and tends to diminish the decrease in MBP by 28%. O1918 also diminishes the fall in MBF and RBF induced by anandamide by 61 and 67% and that induced by methanandamide by 74 and 49% respectively. Cannabidiol does not affect basal cardiovascular parameters whereas O1918 decreases HR by about 15 beats/min and SBP, DBP and MBP by about 15 mmHg. In pithed rats anandamide (3 μmol/kg) causes only an increase in MBF and RBF. The anandamide-induced long-lasting fall in MBP, SBP and DBP is reduced by cannabidiol by 40-46% and by O-1918 by 55, 64 and 35, respectively[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。 分子量：286.41 Formula：C19H26O2 性状：液体 颜色：Colorless to light yellow 运输条件：美国大陆地区的室温；其他地区可能有所不同。 储存方式：溶液，-20°C，2 年 Animal Administration [1]：Rats[1] In order to examine the influence of different receptor antagonists on the changes in cardiovascular parameters induced by anandamide or methanandamide (both in anaesthetized and pithed rats), the particular agonist is injected twice (S1 and S2, 20 min apart). Methanandamide is administered at 0.5 µmol/kg. S1 is applied 5 min after injection of saline solution or ruthenium red 3 (µmol/kg in pithed rats anaesthetized with urethane). Cannabidiol or O1918 (3 µmol/kg) or their solvents are administered 10 min before S2. AM 251, cannabidiol or O1918 (3 µmol/kg, each) are administered simultaneously with pancuronium[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。 文献引用：MCE 顾客使用本产品发表 1 篇科研文献 提供质量检测报告：Data Sheet、SDS、COA、RP-HPLC、产品使用指南 产品活性：O1918 是 non-CB1 受体和 GPR18 的选择性拮抗剂。 IC50 & Target：non-CB1 vascular cannabinoid receptor[1], GPR18[2]. 相关产品：Staurosporine | Staurosporine | Staurosporine (Standard) | Capivasertib | EIPA | FCCP | FCCP (Standard) | CCCP | CCCP (Standard) | SBE-β-CD | α-CGRP (mouse, rat) | Capivasertib (Standard) 热门产品线：抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products：Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向，为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择，助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献： 参考文献： 品牌介绍:
 | |||||||
m.cnreagent.com
